1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. Summary
    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
Delayed Australian Stock Exchange  -  09:01 2022-07-05 pm EDT
286.47 AUD   +2.70%
06/23Seqirus - CDC Advisory Committee Includes FLUAD QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and Older
AQ
06/20EU regulators investigate Vifor Pharma over anti-competitive behaviour
RE
06/10CSL Behring - Acclaimed Photographer Rankin and CSL Behring Team Up to Launch 'Portraits of Progress', an Exhibition Chronicling the Past, Present and Future of Life with Hemophilia
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Australian Stock Exchange
06/29/2022 06/30/2022 07/01/2022 07/04/2022 07/05/2022 Date
269.79(c) 269.06(c) 269.23(c) 274.8(c) 278.94(c) Last
902 274 968 220 948 360 810 065 950 769 Volume
-1.55% -0.27% +0.06% +2.07% +1.51% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 10 730 M - -
Net income 2022 2 275 M - -
Net Debt 2022 7 484 M - -
P/E ratio 2022 38,8x
Yield 2022 1,10%
Sales 2023 13 548 M - -
Net income 2023 2 804 M - -
Net Debt 2023 10 984 M - -
P/E ratio 2023 32,4x
Yield 2023 1,29%
Capitalization 90 967 M 90 967 M -
EV / Sales 2022 9,18x
EV / Sales 2023 7,53x
Nbr of Employees 25 000
Free-Float 95,0%
More Financials
Company
CSL Limited (CSL) is a biotechnology company engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. CSL provides a portfolio of life saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Its segments include CSL Behring and Seqirus. CSL Behring manufactures,... 
Sector
Pharmaceuticals
Calendar
08/17Earnings Release
More about the company
Ratings of CSL Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about CSL LIMITED
06/23Seqirus - CDC Advisory Committee Includes FLUAD QUADRIVALENT as a Preferentially Recomm..
AQ
06/20EU regulators investigate Vifor Pharma over anti-competitive behaviour
RE
06/10CSL Behring - Acclaimed Photographer Rankin and CSL Behring Team Up to Launch 'Portrait..
AQ
06/02Australia shares slide on tech rout, subdued financials
RE
05/31EUCOPE Member Spotlight, Q&A with CSL Behring
AQ
05/23Australian shares subdued as tech, healthcare offset mining gains
RE
05/11Australia shares slide as U.S. inflation data fuels slowdown woes
RE
05/11Australian shares rise on healthcare, mining boost; U.S. inflation data in focus
RE
05/06Australia shares slump as inflation woes hint at more rate hikes
RE
04/20CSL Prices $4 Billion of Bonds in US Debt Market
MT
04/20PAUL RAMSAY : KKR-led group offers record $14.8 billion bid for Australia's Ramsay Health
RE
03/31Australia shares inch lower on tech, energy losses
RE
03/29CSL Behring - European Medicines Agency Commences Review of Novel Gene Therapy Candidat..
AQ
03/28Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Q..
AQ
03/23CSL BEHRING AG - PUBLICATION OF PROV : Participation rate of 94 percent
AQ
More news
News in other languages on CSL LIMITED
06/20Vifor Pharma dans le viseur du gendarme européen de la concurrence
06/20Les régulateurs de l'UE enquêtent sur Vifor Pharma pour comportement anticoncurrentiel
05/12La reprise de Vifor pourrait ne pas être bouclée d'ici fin juin
05/12Abschluss der Vifor-Übernahme durch CSL verzögert sich
04/20CSL fixe le prix de 4 milliards de dollars d'obligations sur le marché américain de la ..
More news
Analyst Recommendations on CSL LIMITED
More recommendations
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 188,84 $
Average target price 216,68 $
Spread / Average Target 14,7%
EPS Revisions
Managers and Directors
Paul Roger Perreault Chief Executive Officer, MD & Executive Director
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
Andrew Nash Chief Scientific Officer, SVP & Head-Research
William Mezzanotte CMO, Executive VP, Head-Research & Development